IGC Pharma, Inc.IGCEarnings & Financial Report
NYSE
NextMar 13, 2026
IGC Q3 2025 Key Financial Metrics
Revenue
$191.0K
Gross Profit
$99.0K
Operating Profit
$-2.9M
Net Profit
$-1.8M
Gross Margin
51.8%
Operating Margin
-1517.8%
Net Margin
-953.4%
YoY Growth
-53.6%
EPS
$-0.02
Financial Flow
IGC Pharma, Inc. Q3 2025 Financial Summary
IGC Pharma, Inc. reported revenue of $191.0K for Q3 2025, with a net profit of $-1.8M (-953.4% margin). Cost of goods sold was $92.0K, operating expenses totaled $3.0M.
Key Financial Metrics
| Total Revenue | $191.0K |
|---|---|
| Net Profit | $-1.8M |
| Gross Margin | 51.8% |
| Operating Margin | -1517.8% |
| Report Period | Q3 2025 |
IGC Pharma, Inc. Annual Revenue by Year
IGC Pharma, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $1.2M).
| Year | Annual Revenue |
|---|---|
| 2024 | $1.2M |
| 2023 | $1.2M |
| 2022 | $868.0K |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $204000 | $295000 | $272000 | $412000 | $257000 | $330000 | $328000 | $191000 |
| YoY Growth | -38.6% | 78.8% | -51.0% | 41.6% | 26.0% | 11.9% | 20.6% | -53.6% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $11.3M | $9.9M | $10.6M | $10.4M | $9.1M | $8.7M | $7.9M | $9.7M |
| Liabilities | $2.2M | $2.6M | $2.7M | $3.0M | $2.8M | $2.4M | $1.9M | $1.7M |
| Equity | $9.1M | $7.3M | $7.9M | $7.4M | $6.3M | $6.3M | $6.1M | $8.1M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-1.6M | $-526000 | $-1.8M | $-996000 | $-1.3M | $-730000 | $-1.4M | $-2.1M |